BACKGROUND: The objective of the current study was to evaluate the efficacy of intensive chemotherapy with and without cranial radiation for central nervous system (CNS) prophylaxis in adults with Burkitt leukemia or lymphoma. METHODS: Patients received 18 weeks of therapy. Prophylactic cranial radiation (2400 centigrays) and 12 doses of triple intrathecal chemotherapy were administered to the first cohort of patients. A subsequent cohort received the same therapy, with the exceptions that intrathecal therapy was reduced to six doses and radiotherapy was administered only to high-risk individuals. RESULTS: The median follow-up durations were 6.8 years in Cohort 1 and 4.1 years in Cohort 2. Three occurrences of transverse myelitis, 2 severe neuropathies, 3 cases of aphasia, and 1 case of blindness were documented in the first cohort of 52 patients (Cohort 1). In the subsequent cohort of 40 patients (Cohort 2), none of these occurrences were observed, and patients experienced less neurologic toxicity overall (61% vs. 26%; P=0.001). Responses were similar, and the 3-year event-free survival rate was 0.52 (95% confidence interval, 0.38-0.65) for Cohort 1 and 0.45 (0.29-0.60) for Cohort 2. CONCLUSIONS: Intensive, short-duration chemotherapy with less intensive CNS prophylaxis led to control at this sanctuary site with little neurotoxicity and may be curative for adults with Burkitt leukemia or lymphoma. Copyright 2004 by the American Cancer Society.
BACKGROUND: The objective of the current study was to evaluate the efficacy of intensive chemotherapy with and without cranial radiation for central nervous system (CNS) prophylaxis in adults with Burkitt leukemia or lymphoma. METHODS:Patients received 18 weeks of therapy. Prophylactic cranial radiation (2400 centigrays) and 12 doses of triple intrathecal chemotherapy were administered to the first cohort of patients. A subsequent cohort received the same therapy, with the exceptions that intrathecal therapy was reduced to six doses and radiotherapy was administered only to high-risk individuals. RESULTS: The median follow-up durations were 6.8 years in Cohort 1 and 4.1 years in Cohort 2. Three occurrences of transverse myelitis, 2 severe neuropathies, 3 cases of aphasia, and 1 case of blindness were documented in the first cohort of 52 patients (Cohort 1). In the subsequent cohort of 40 patients (Cohort 2), none of these occurrences were observed, and patients experienced less neurologic toxicity overall (61% vs. 26%; P=0.001). Responses were similar, and the 3-year event-free survival rate was 0.52 (95% confidence interval, 0.38-0.65) for Cohort 1 and 0.45 (0.29-0.60) for Cohort 2. CONCLUSIONS: Intensive, short-duration chemotherapy with less intensive CNS prophylaxis led to control at this sanctuary site with little neurotoxicity and may be curative for adults with Burkitt leukemia or lymphoma. Copyright 2004 by the American Cancer Society.
Authors: Mark Roschewski; Kieron Dunleavy; Jeremy S Abramson; Bayard L Powell; Brian K Link; Prapti Patel; Philip J Bierman; Deepa Jagadeesh; Ronald T Mitsuyasu; David Peace; Peter R Watson; Wahid T Hanna; Christopher Melani; Andrea N Lucas; Seth M Steinberg; Stefania Pittaluga; Elaine S Jaffe; Jonathan W Friedberg; Brad S Kahl; Richard F Little; Nancy L Bartlett; Michelle A Fanale; Ariela Noy; Wyndham H Wilson Journal: J Clin Oncol Date: 2020-05-26 Impact factor: 44.544
Authors: Stacey M Parker; Horatiu Olteanu; Peter VanTuinen; Colleen A Lawton; Christopher J Schultz; Kathleen K Christians; Timothy S Fenske Journal: Int J Hematol Date: 2009-11-25 Impact factor: 2.490
Authors: Jennifer L Kelly; Stephen R Toothaker; Lauren Ciminello; Dieter Hoelzer; Harald Holte; Ann S LaCasce; Graham Mead; Deborah Thomas; Gustaaf W Van Imhoff; Brad S Kahl; Bruce D Cheson; Ian T Magrath; Richard I Fisher; Jonathan W Friedberg Journal: Clin Lymphoma Myeloma Date: 2009-08
Authors: Leena V Maramattom; Parameswaran N Hari; Linda J Burns; Jeanette Carreras; William Arcese; Mitchell S Cairo; Luciano J Costa; Timothy S Fenske; Michael Lill; Cesar O Freytes; Robert Peter Gale; Thomas G Gross; Gregory A Hale; Mehdi Hamadani; Leona A Holmberg; Jack W Hsu; David J Inwards; Hillard M Lazarus; David I Marks; David G Maloney; Richard T Maziarz; Silvia Montoto; David A Rizzieri; Baldeep Wirk; James L Gajewski Journal: Biol Blood Marrow Transplant Date: 2012-11-27 Impact factor: 5.742
Authors: David A Rizzieri; Jeffrey L Johnson; John C Byrd; Gerard Lozanski; Kristie A Blum; Bayard L Powell; Thomas C Shea; Sreenivasa Nattam; Eva Hoke; Bruce D Cheson; Richard A Larson Journal: Br J Haematol Date: 2014-01-15 Impact factor: 6.998
Authors: Yvette L Kasamon; Robert A Brodsky; Michael J Borowitz; Richard F Ambinder; Pamela A Crilley; Steve Y Cho; Hua-ling Tsai; B Douglas Smith; Douglas E Gladstone; Hetty E Carraway; Carol Ann Huff; William H Matsui; Javier Bolaños-Meade; Richard J Jones; Lode J Swinnen Journal: Leuk Lymphoma Date: 2012-08-17
Authors: Graham M Mead; Sharon L Barrans; Wendi Qian; Jan Walewski; John A Radford; Max Wolf; Simon M Clawson; Sally P Stenning; Claire L Yule; Andrew S Jack Journal: Blood Date: 2008-07-08 Impact factor: 22.113